Literature DB >> 18399284

Comparative study of preventive and therapeutic effects of IEM-1966 and memantine in rats with experimental allergic encephalomyelitis.

I N Abdurasulova1, S E Serdyuk, V E Gmiro.   

Abstract

We compared preventive and therapeutic effects of memantine, a selective blocker of NMDA-receptors, and IEM-1966, a blocker of both NMDA- and GluR1 AMPA-receptors, on the model of acute experimental allergic encephalomyelitis. Memantine in high doses prevented the development of experimental allergic encephalomyelitis only in 10% rats, slightly (by 1.4-1.5 times) moderated the neurological disturbances, and shortened the duration of the disease. In far lower doses, IEM-1966 prevented the development of experimental allergic encephalomyelitis in 50% rats, while in the affected rats it decreased the severity of neurological disturbances and duration of the disease by 3-4 times. When applied during the clinical phase of the disease, IEM-1966 decreased the severity of neurological disturbances and duration of the disease by 2.0-2.5 times predominantly in rats with mild and moderate course of experimental allergic encephalomyelitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18399284     DOI: 10.1007/s10517-007-0293-6

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Inhibition of NR2B-Containing N-methyl-D-Aspartate Receptors (NMDARs) in Experimental Autoimmune Encephalomyelitis, a Model of Multiple Sclerosis.

Authors:  Mojtaba Farjam; Faegheh Baha'addini Beigi Zarandi; Shirin Farjadian; Bita Geramizadeh; Ali Reza Nikseresht; Mohammad Reza Panjehshahin
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

2.  Memantine Modulates Oxidative Stress in the Rat Brain following Experimental Autoimmune Encephalomyelitis.

Authors:  Beata Dąbrowska-Bouta; Lidia Strużyńska; Marta Sidoryk-Węgrzynowicz; Grzegorz Sulkowski
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.